Abbvie Inc. (ABBV)

From the record

Abbvie Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Abbvie Inc.'s 10 filed years say what it did: revenue went from $26 billion in fiscal 2016 to $61 billion in fiscal 2025, up 10.1% a year; it rose in 8 of 9 years; the deepest fall was 6% from fiscal 2022 to fiscal 2023; net income was positive in 10 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Abbvie Inc.'s diluted share count shrank about 0.1% a year, and dividends and buybacks returned about 62% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 7 sales (4 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-12 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Abbvie Inc.'s shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 32 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 102 cents per dollar of assets, and net share issuance: its share count was unchanged over the year (the filed statements).

From the record

Abbvie Inc.'s standing among 315 graded names in its industry family: revenue of $61 billion in fiscal 2025 ranks in the top 2% by size; a net margin of 6.8% ranks in the top 19%; revenue growth of 1.8% a year over the last 3 filed years ranks in the bottom 41% (its annual reports).

From the record

Abbvie Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Michael, Robert A. (CHAIRMAN OF THE BOARD AND CEO, as filed), filing under that title since 2025-02-18, 1.7 years (bottom 21% of its family); the 21 officers and directors filing in the last fifteen months have been on the record a median of 8.5 years (top 16%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 21 people in charge now (top 33%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Abbvie Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $5.2 billion against debt of $59 billion leaves -40.1% of its assets as net cash, bottom 3% of its family; cash from operations less capital spending is 29.1% of revenue (top 7%); a gross margin of 70.2% (bottom 49%); research spending of 14.9% of revenue (bottom 19%) (its annual report).

From the record

Abbvie Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 1.8% a year over the last three filed years against 10.1% over all 10, slowing (bottom 38% of its family); the newest year grew 8.6% (top 49%); research spending grew 11.8% a year (top 36%); capital spending grew 20.4% a year (top 24%) (its annual reports). Abbvie Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Abbvie Inc.'s newest year against its own record: revenue of $61 billion in fiscal 2025 came in 10.2% above the $55 billion its prior three years' pace pointed to (top 33% of its family); net income of $4.2 billion against a prior three-year average of $6.9 billion (bottom 29%); a net margin of 6.8% against 12.2% before (bottom 32%) (its annual reports).